Amgen Inc.
Amgen Reports Strong Third Quarter 2025 Financial Results
Summary
Amgen Inc. reported its financial results for the third quarter of 2025, showing total revenues of $9.6 billion, a 12% increase from the same period in 2024. Product sales grew 12%, driven by 14% volume growth, partially offset by a 4% lower net selling price. GAAP earnings per share (EPS) increased 14% to $5.93, while non-GAAP EPS increased 1% to $5.64. The company generated $4.2 billion in free cash flow. Amgen also provided its full-year 2025 guidance, expecting total revenues between $35.8 billion and $36.6 billion, with GAAP EPS guidance of $13.76 to $14.60 and non-GAAP EPS guidance of $20.60 to $21.40.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement